A股市场和港股市场今天（6月9日）上午盘中均明显走强，其中A股市场上证指数盘中一度突破3400点整数关口，生物医药板块领涨。 非银金融板块大幅上涨。信达证券、永安期货、南华期货盘中触及涨停。另外，东兴证券、弘业期货、中国银河、瑞达期货、光大证券等多股跟涨。消息面上，近 日证监会官网披露，长城国瑞证券、东兴证券、信达证券、东兴基金、信达澳亚基金、长城期货、东兴期货、信达期货的变更实际控制人申请文件已获核准，中央 汇金投资有限责任公司成为其实际控制人。 家用电器、有色金属等板块上午盘中走低。 概念板块方面，CXO概念、减肥药概念等概念板块涨幅居前。 5月CPI和PPI出炉。国家统计局今天发布的数据显示，2025年5月份，全国居民消费价格同比下降0.1%。其中，城市持平，农村下降0.4%；食品价格下降0.4%，非食 品价格持平；消费品价格下降0.5%，服务价格上涨0.5%。1—5月平均，全国居民消费价格比上年同期下降0.1%。 5月份，全国居民消费价格环比下降0.2%。其中，城市下降0.2%，农村下降0.2%；食品价格下降0.2%，非食品价格下降0.2%；消费品价格下降0.3%，服务价格持 平。 A股市场今天上午盘 ...

Core Insights - ibex will showcase its AI-powered customer experience (CX) solutions at the CCW Customer Contact Week in Las Vegas from June 9-12, 2025, highlighting its leadership in the industry [1][6] - The company emphasizes its combination of over 20 years of CX expertise with cutting-edge AI technology to enhance customer interactions and drive growth [2][4] - ibex will host a Fireside Chat on June 11, focusing on real-world AI implementation best practices, featuring industry leaders [2][8] Company Overview - ibex is a global provider of business process outsourcing (BPO) and AI-powered customer engagement technology solutions, operating approximately 30 facilities worldwide [4] - The company employs over 31,000 individuals and manages nearly 175 million customer interactions annually, contributing over $2.2 billion in lifetime customer revenue each year [5] Event Highlights - The CCW event will feature live demonstrations of ibex's Wave iX AI solutions, including the AI Virtual Agent and Wave iX Translate, which supports real-time interactions in over 150 languages [2] - The 2025 CX Leadership Awards will be presented at an exclusive dinner, recognizing individuals and companies that excel in customer engagement and experience [2][3]

Freshworks (FRSH) 2025 Conference Summary Company Overview - Freshworks is focused on scaling its operations, particularly in the SMB (Small and Medium-sized Business) sector, with a strong emphasis on AI integration and customer satisfaction [5][6]. Key Industry Insights - The adoption of AI, particularly through the Freddie Copilot, has accelerated among customers, with a current attach rate exceeding 20% [9]. - Customers are increasingly seeking efficiencies and improved customer satisfaction rather than merely cost-cutting measures [13]. - The company has seen a 7% growth in Annual Recurring Revenue (ARR) in its CX (Customer Experience) business, which is consistent with previous quarters [29]. Core Business Strategies - Freshworks is focusing on enhancing customer satisfaction and retention while driving efficiency through AI solutions [13]. - The company is shifting its pricing strategy towards more intuitive models, such as usage-based pricing, although current pricing remains per agent [18][19]. - Freshworks is actively revamping its partner relationships to foster more collaborative and performance-based partnerships [39][40]. Customer Engagement and Market Position - Customers are increasingly asking for integrated solutions that streamline interactions across multiple channels, including voice, social media, and email [45]. - The company has a strong competitive position against larger firms like Zendesk and ServiceNow, primarily due to its simplicity and cost-effectiveness [66][71]. - Freshworks has implemented a strategy to convert free users to paid plans by limiting the number of free agents and the duration of free usage, resulting in significant conversion rates [82][84]. Financial Performance and Growth Opportunities - The company is experiencing healthy expansion in its business, particularly in AI investments and add-ons, which are contributing to increased Average Contract Value (ACV) [14][15]. - Freshworks is seeing a trend where customers are willing to invest in solutions that promise faster ROI, even amidst macroeconomic uncertainties [60][62]. Future Outlook - The company is preparing for upcoming product announcements and innovations aimed at enhancing customer experience and operational efficiency [26][34]. - Freshworks is committed to maintaining its focus on the SMB market, which is less complex and more aligned with its product offerings compared to larger enterprises [72][75]. Additional Insights - The macroeconomic environment has not deterred customers from investing; instead, it has prompted them to seek solutions that offer greater efficiencies [63]. - Freshworks is leveraging its existing customer base to demonstrate the effectiveness of its AI solutions, which is a significant selling point in competitive scenarios [46][50].

一顿操作猛如虎，目前已有27382只基金更新净值，谁是基金中的王者，谁又垫底，请看数据： 混合A、恒越内需驱动混合C。 | 排名 | 代码 | 基金简称 | 2025-06-03 | | 2025-05-30 | | 程机号 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 車位净值8 | 累计净值8 | 单位净值3 | 累计净值3 | | | 1 | 515210 | 国泰中证钢铁ETF | 1.1848 | 1.3498 | 1.2022 | 1.3672 | -0.01 | | 2 | 159730 | 博时龙头家电ETF | 0.9686 | 0.9686 | 0.9822 | 0.9822 | -0.01 | | 3 | 016815 | 国联钢铁C | 1.0810 | 1.0810 | 1.0960 | 1.0960 | -0.01 | | 4 | 008190 | 国泰中证钢铁ETF联接C | 1.1462 | 1.3462 | 1.1621 | 1.3621 | -0.01 | | 5 | 159512 | 广发中证全指汽 ...

点击 关注我们 报告发布日期：2025年5月28日 报告名称: 《澜起科技（688008.SH）：聚焦高速互连芯片，运力芯片成为增长新引擎》 分析师：胡剑 S0980521080001/胡慧 S0980521080002/ 叶 子 S0980522100003 / 张大为 S0980524100002/ 詹浏洋 S0980524060001 / 李书颖 S0980122080309 联系人：连欣然 完整报告请扫描下方二维码 核心观点 2024年互连类芯片和津逮服务器平台收入占比分别为92%和8%，1Q25收入和归母净利润均创季度 新高 在数据密集的计算系统中，CXL可用于内存扩展、内存池化和内存共享。公司的MXC芯片是一款CXL内存扩 展控制器芯片，已成功通过了CXL 2.0合规性测试，列入CXL联盟公布的首批CXL 2.0合规供应商清单；另外， 三星和SK海力士同期入选CXL 2.0合规供应商清单，其受测产品均采用了公司的MXC芯片。另外，公司在 2024年第四季度决定暂缓用于数据中心的AI算力芯片研发，将相关技术积累和研发资源转移至PCIe Switch芯 片的研发及产业化。 风险提示 新产品研发不及预期 ...

Group 1 - The core viewpoint is that the pharmaceutical industry is expected to experience stable growth driven by innovation, policy optimization, and increasing clinical demand due to aging demographics [3] - The National Biopharmaceutical Index (399441) has shown a strong increase of 1.83%, with key stocks like Kylin Pharmaceutical (002821) rising by 5.51% and Zhaoyan New Drug (603127) by 4.66% [1] - The Biopharmaceutical ETF (159839) has seen a cumulative increase of 1.54% over the past two weeks, indicating positive market sentiment [1] Group 2 - Open Source Securities emphasizes that the pharmaceutical sector will benefit from improved drug procurement policies and a favorable external environment, leading to a recovery in the healthcare industry [3] - Citic Securities notes that the pharmaceutical sector achieved its best market returns in the first half of 2025, driven by policy trends and the maturation of pharmaceutical innovation [3] - The current PEG levels for most growth-oriented pharmaceutical companies are below 1, suggesting potential for performance and valuation recovery [3]

Investment Rating - The report maintains an "Outperform" rating for the company [5]. Core Views - The company focuses on high-speed interconnect chips, with its capacity chips becoming a new growth engine. In 2024, interconnect chips and the Tsingdai server platform accounted for 92% and 8% of revenue, respectively. The company achieved a revenue of 3.639 billion yuan in 2024, a year-on-year increase of 59%, and a net profit of 1.412 billion yuan, a year-on-year increase of 213% [1][11]. - The company is one of the three major DDR5 memory interface chip manufacturers globally, leading the second-generation iteration of DDR5. The continuous iteration of CPUs supporting higher-speed DDR5 will drive the large-scale use and upgrade of DDR5 memory modules [2][45]. - The MXC chip has entered the first batch of compliant suppliers for CXL 2.0, and the company has decided to shift its R&D focus from AI computing chips for data centers to PCIe Switch chips [3][12]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 3.639 billion yuan, with a year-on-year growth of 59%. The net profit reached 1.412 billion yuan, marking a year-on-year increase of 213%. The revenue and net profit for Q1 2025 were 1.222 billion yuan and 525 million yuan, respectively, both setting quarterly records [1][11][16]. - The company's revenue from interconnect chips was 3.349 billion yuan, with a gross margin of 62.7% in 2024 [24][22]. Product Development - The company has successfully launched multiple high-performance capacity chips, including PCIe Retimer, MRCD/MDB, and CKD, with a combined revenue of approximately 422 million yuan in 2024, which is eight times that of 2023 [2][56]. - The company has initiated the second-generation iteration of DDR5 memory interface chips, with the second-generation RCD chip shipments exceeding those of the first generation in 2024 [46][45]. Market Position - The company is positioned as a leading provider of interconnect chips and server platforms, with a CAGR of 20% in revenue from 2016 to 2024 and a CAGR of 41% in net profit during the same period [11][16]. - The global market for memory interface chips is expected to reach $5.7 billion by 2031, with the company being one of the three main suppliers [40][41]. Valuation - The report provides a reasonable valuation range for the company's stock at 84.50 to 93.89 yuan, representing a premium of 11% to 24% over the closing price of 75.84 yuan on May 27 [5][4].

A股市场今天（5月28日）窄幅震荡，主要指数小幅下跌。截至收盘，上证指数跌0.02%，深证成指跌 0.26%，创业板指跌0.31%，科创50指数跌0.23%，北证50指数跌1.39%。 比亚迪（002594）刷屏。 A股市场主要股指今天（5月28日）走低，食品饮料板块表现较好。 个股方面，整体表现分化，多只人气股高台"跳水"，但也有不少股票连续涨停。 此外，比亚迪A股和H股双双跌超2%，其中H股一度大跌超3%，该股已连跌三个交易日。近期，关 于"比亚迪山东经销商爆雷"的消息持续刷屏。 A股市场主要股指走低 行业板块和赛道方面，食品饮料板块领涨，板块涨幅超过1.5%，欢乐家（300997）"20cm"涨停，新乳 业（002946）、均瑶健康（605388）等股票涨停，东鹏饮料（605499）、李子园（605337）、阳光乳业 （001318）等股票大幅上涨。 | 代码 | 名称 | | 涨幅% | 现价 | 涨跌 | 采价 | 更价 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300997 | 欢乐家 | R | 20.01 | 20.87 | 3 ...

比亚迪刷屏。 A 股市场主要股指今天（ 5 月 28 日）走低 ， 食品饮料板块表现较好。 个股方面，整体表现分化，多只人气股高台"跳水"，但也有不少股票连续涨停。 此外，比亚迪A股和H股双双跌超2%，其中H股一度大跌超3%，该股已连跌三个交易日。近期，关于"比亚迪山东经销商爆雷"的消息持续刷屏。 A股市场主要股指走低 A股市场今天（5月28日）窄幅震荡，主要指数小幅下跌。截至收盘，上证指数跌0.02%，深证成指跌0.26%，创业板指跌0.31%，科创50指数跌0.23%，北证50指数 跌1.39%。 行业板块和赛道方面，食品饮料板块领涨，板块涨幅超过1.5%，欢乐家"20cm"涨停，新乳业、均瑶健康等股票涨停，东鹏饮料、李子园、阳光乳业等股票大幅上 涨。 | 代码 | 名称 | . | 涨幅% | 现价 | 涨跌 | 买价 | 更价 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300997 | 欢乐家 | R | 20.01 | 20.87 | 3.48 | 20.87 | | | 002946 | 新乳V | R | 10.03 | 19.9 ...

注：指数/基金短期涨跌幅及历史表现仅供分析参考，不预示未来表现。市场观点随市场环境变化而变 动，不构成任何投资建议或承诺。文中提及指数仅供参考，不构成任何投资建议，也不构成对基金业绩 的预测和保证。如需购买相关基金产品，请选择与风险等级相匹配的产品。基金有风险，投资需谨慎。 （文章来源：每日经济新闻） 疫苗板块基本面承压但部分重点公司业绩边际改善，关注带疱等增量方向及HPV国产高性价比厂商渗透 潜力。中医药领域建议关注与生育补贴相关的标的。医疗器械方面，集采推进加速替代，重点关注电生 理、神经介入等领域的替代潜力。低值耗材行业下游去库逐渐完成，关注周期上行机会及GLP-1产业链 潜力。 疫苗ETF（159643）跟踪的是疫苗生科指数（980015），该指数由中证指数有限公司编制，从A股市场 中选取涉及疫苗研发、生产和销售以及相关生物科技领域的上市公司证券作为指数样本。疫苗生科指数 聚焦医药生物板块，旨在反映疫苗与生物科技相关上市公司的整体表现。 民生证券指出，医药生物行业创新药板块催化不断，作为全年医药主线，重点关注抗肿瘤、自免、 GLP-1、干细胞、基因治疗等方向。CXO板块在国内全链条鼓励创新药物发展政策 ...